Celon Pharma SA (CLN) — Tangible Net Worth Ratio
Celon Pharma SA (CLN) has a Tangible Net Worth Ratio of 100.0% as of December 2025. This metric is calculated by deducting intangible assets (zł0.00) from net assets (zł363.25 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Celon Pharma SA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Celon Pharma SA Tangible Net Worth Ratio (2012–2025)
This chart shows how Celon Pharma SA's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 100.0%, reflecting net assets of zł363.25 Million with intangible assets of zł0.00 PLN. See CLN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Celon Pharma SA (2012–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Celon Pharma SA from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Celon Pharma SA market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (PLN) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | zł363.25 Million | zł0.00 | zł457.46 Million | ▲ +1.8 pp |
| 2024 | 98.2% | zł445.21 Million | zł8.15 Million | zł543.79 Million | ▲ +1.5 pp |
| 2023 | 96.6% | zł445.56 Million | zł14.97 Million | zł569.31 Million | ▲ +2.5 pp |
| 2022 | 94.1% | zł479.65 Million | zł28.12 Million | zł608.93 Million | ▼ -0.6 pp |
| 2021 | 94.7% | zł554.00 Million | zł29.17 Million | zł707.14 Million | ▲ +4.2 pp |
| 2020 | 90.5% | zł434.67 Million | zł41.09 Million | zł703.64 Million | ▼ -8.1 pp |
| 2019 | 98.6% | zł445.04 Million | zł6.16 Million | zł591.35 Million | ▲ +0.3 pp |
| 2018 | 98.3% | zł448.73 Million | zł7.41 Million | zł563.67 Million | ▼ -1.1 pp |
| 2017 | 99.4% | zł439.85 Million | zł2.64 Million | zł525.05 Million | ▲ +0.2 pp |
| 2016 | 99.2% | zł402.50 Million | zł3.36 Million | zł464.32 Million | ▲ +2.1 pp |
| 2015 | 97.1% | zł100.82 Million | zł2.97 Million | zł168.29 Million | ▼ -1.6 pp |
| 2014 | 98.7% | zł69.62 Million | zł904.73K | zł105.44 Million | ▼ -0.5 pp |
| 2013 | 99.2% | zł52.20 Million | zł407.81K | zł82.59 Million | ▲ +0.1 pp |
| 2012 | 99.1% | zł55.57 Million | zł479.61K | zł69.80 Million | — |